Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,261 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | Phase 3 | terminated | Sep 19, 2005 | Japan Clinical Oncology Group | not stated | Not stated |
| NCT02895503 | Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing… | N/A | terminated | Sep 9, 2016 | Virginia Commonwealth University | Lack of accrual/Slow accrual | Enrollment / accrual |
| NCT00807170 | Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain… | Phase 1 | terminated | Dec 11, 2008 | Sanofi | Very slow recruitment | Enrollment / accrual |
| NCT02126527 | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent… | Phase 1 | withdrawn | Apr 30, 2014 | Mayo Clinic | no participants enrolled | Enrollment / accrual |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in… | Phase 2 | terminated | Nov 29, 2006 | Hoffmann-La Roche | Primary (safety) endpoint reached | Safety / toxicity |
| NCT02522910 | An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Yonsei University | not stated | Not stated |
| NCT01915524 | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small… | Phase 1 | terminated | Aug 5, 2013 | CureVac | Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT02673814 | Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously… | Phase 2 | withdrawn | Feb 4, 2016 | Peregrine Pharmaceuticals | not stated | Not stated |
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage… | Phase 1 / Phase 2 | terminated | Dec 29, 2006 | Nasser Hanna, M.D. | Negative sorafenib results from ESCAPE trial and safety concerns of regimen | Safety / toxicity |
| NCT01137162 | Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors | — | terminated | Jun 4, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT02419170 | Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With… | Early Phase 1 | withdrawn | Apr 17, 2015 | Washington University School of Medicine | Investigator who manufactured the vaccine left the university. | Drug supply |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer… | Phase 2 | withdrawn | Jun 2, 2014 | AHS Cancer Control Alberta | contract issues | Other (stated, no rule matched) |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in…(Galaxy 2) | Phase 3 | terminated | Feb 25, 2013 | Synta Pharmaceuticals Corp. | The study was stopped after the first Interim Analysis due to futility. | Efficacy / futility |
| NCT00787267 | Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC(TOP0801) | Phase 2 | terminated | Nov 7, 2008 | Duke University | Poor accrual | Enrollment / accrual |
| NCT02277457 | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy… | Early Phase 1 | withdrawn | Oct 29, 2014 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT02087176 | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat… | Phase 2 | terminated | Mar 14, 2014 | AstraZeneca | The study was terminated early by the sponsor. | Other (stated, no rule matched) |
| NCT02705339 | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Phase 2 | withdrawn | Mar 10, 2016 | Washington University School of Medicine | Clovis Oncology discontinued rociletinib. | Other (stated, no rule matched) |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Phase 2 | terminated | Jan 30, 2015 | Erin Bertino | Low patient accrual | Enrollment / accrual |
| NCT02651506 | Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the… | Phase 2 | withdrawn | Jan 11, 2016 | St. Joseph's Healthcare Hamilton | not stated | Not stated |
| NCT00692380 | Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable… | Phase 1 | terminated | Jun 6, 2008 | Virginia Commonwealth University | insufficient accrual | Enrollment / accrual |
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | Phase 2 | terminated | Aug 11, 2008 | Hoosier Cancer Research Network | Study terminated due to withdrawal of pharmaceutical funding | Funding |
| NCT00766246 | Phase II Avastin Trial for Stage IIIB/IV NSCLC | Phase 2 | terminated | Oct 3, 2008 | Pharmatech | Withdrawal of funding support | Funding |
| NCT01058902 | The Effect Of Aspirin On Survival in Lung Cancer | Phase 3 | withdrawn | Jan 29, 2010 | Liverpool Heart and Chest Hospital NHS Foundation Trust | failed to achive funding | Funding |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | Phase 2 | terminated | Mar 27, 2013 | National OncoVenture | Low recruitment | Enrollment / accrual |
| NCT01525446 | Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer | Early Phase 1 | terminated | Feb 3, 2012 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT01565772 | Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III… | Phase 1 | terminated | Mar 29, 2012 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT02537561 | Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 1, 2015 | Washington University School of Medicine | The pharmaceutical company did not want to follow through with support for the study. | Sponsor / business decision |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of… | Phase 3 | terminated | Dec 22, 2008 | Danish Oncological Lung Cancer Group | Slow accrual | Enrollment / accrual |
| NCT02470065 | Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.(REMNANT) | Phase 2 | suspended | Jun 12, 2015 | European Organisation for Research and Treatment of Cancer - EORTC | Study never started | Other (stated, no rule matched) |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of…(DISTAL-2) | Phase 3 | terminated | Jun 27, 2006 | National Cancer Institute, Naples | slow accrual | Enrollment / accrual |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | Phase 2 | terminated | Mar 6, 2006 | Bayer | Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the… | Efficacy / futility |
| NCT00986284 | Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non… | Phase 2 | suspended | Sep 29, 2009 | Tianjin Medical University Cancer Institute and Hospital | Lack of patients and some progressed disease soon after surgery | Other (stated, no rule matched) |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced… | Phase 3 | terminated | Dec 14, 2015 | Takeda | Sponsor decision to terminate the study because the study did not meet the primary endpoint. | Sponsor / business decision |
| NCT01193868 | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently… | Phase 2 | terminated | Sep 2, 2010 | National Cancer Institute (NCI) | Study drug production halted. | Other (stated, no rule matched) |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction… | Phase 2 | terminated | Jul 9, 2010 | National Cancer Center, Korea | low enrolling participants | Enrollment / accrual |
| NCT01577212 | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern…(IDEAL-VMAT) | Phase 2 | terminated | Apr 13, 2012 | Radboud University Medical Center | Lack of accrual | Enrollment / accrual |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | Phase 2 / Phase 3 | terminated | May 5, 2011 | Synta Pharmaceuticals Corp. | not stated | Not stated |
| NCT01411098 | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung… | Phase 1 | terminated | Aug 8, 2011 | University of Washington | Low accrual | Enrollment / accrual |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 / Phase 2 | withdrawn | Sep 1, 2015 | Erin Bertino | PI decision due to funding support | Funding |
| NCT00738881 | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating…(MARVEL) | Phase 3 | terminated | Aug 21, 2008 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell… | Phase 2 | withdrawn | Oct 7, 2008 | Eli Lilly and Company | not stated | Not stated |
| NCT00905801 | Computed Tomography (CT) Perfusion Imaging of Lung Cancer | N/A | terminated | May 21, 2009 | University of Pittsburgh | Co-PI left institution, PI not pursuing | Investigator |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment… | Phase 2 | terminated | Feb 25, 2009 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 18, 2008 | University Hospital of Crete | not stated | Not stated |
| NCT02134886 | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or… | Phase 1 | terminated | May 9, 2014 | National Cancer Institute (NCI) | No Accrual | Enrollment / accrual |
| NCT01004419 | Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Oct 30, 2009 | University of Wisconsin, Madison | Support for investigational products has been withdrawn. | Other (stated, no rule matched) |
| NCT00923949 | Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Study never published; terminated early due to low accrual. | Enrollment / accrual |
| NCT01946490 | Time Trends in Waiting Times of NSCLC Patients. | — | withdrawn | Sep 19, 2013 | Maastricht Radiation Oncology | Not subsidized, will not start in the near future | Other (stated, no rule matched) |
| NCT01193881 | RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent… | Phase 1 | terminated | Sep 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 12, 2016source: clinicaltrials